Neurotech International Ltd. (AU:NTI) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurotech International Ltd has announced promising results from their Phase I/II clinical trial, showing that their drug NTI164 can normalize immune system gene expression in children with PANDAS/PANS, a condition linked to severe neuropsychiatric symptoms. This genomic analysis supports earlier findings that NTI164 can safely modulate immune and epigenetic factors, potentially offering significant therapeutic benefits. Investors may find these developments encouraging as the company continues to advance its biopharmaceutical innovations in pediatric neurological disorders.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.